FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	DC	20549	
rvasiliigtoii,	D.C.	20343	

STATEMENT	OF CHANGES	IN BENEFICIAL	OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Nighan Warren JR						2. Issuer Name and Ticker or Trading Symbol HAEMONETICS CORP [HAE]								5. Relationship of Reporting Person(s) to Issue (Check all applicable) Director 10% Own			vner	
(Last) 400 WOO	(Fir	est)	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 07/24/2013							–	X Officer (give title Other (specify below) EVP, Global QA/RA				
(Street) BRAINTE	REE MA	A	02184		4. 1	4. If Amendment, Date of Original Filed (Month/Day/Year)					Line)	X Form filed by One Reporting Person Form filed by More than One Reporting						
(City)	(Sta	ate)	(Zip)											Person				
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
D D		Date	2. Transaction Oate Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		Code	Transaction Disposed Code (Instr.		es Acquired (A) or Of (D) (Instr. 3, 4 and		Beneficial Owned Fo	ly	Form:	Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
								Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)					
Common S	Stock											7,618			D			
											osed of, o convertible			wned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution D if any (Month/Day/	ate, T	ransa Code (ansaction of Expode (Instr. Derivative (Mo		6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and An of Securities Underlying Derivative Sec (Instr. 3 and 4)		es g Security	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securitie Beneficia Owned Following Reported Transact (Instr. 4)	e s ally g	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)			
				c	Code	v	(A)	(D)	Date Exercisal		Expiration Date	Title	Amount or Number of Shares					
Performance Shares	\$0.0	07/24/2013			A		25,000		03/31/201	L7 ⁽¹⁾	12/31/2017 ⁽¹⁾	Common Stock	25,000	\$0.0	25,00)0	D	
Non- Qualified Stock Option (right to buy)	\$29.715								01/26/201	12 ⁽²⁾	01/26/2018	Common Stock	18,772		18,77	72	D	
Non- Qualified Stock Option (right to buy)	\$30.67								10/25/203	12 ⁽²⁾	10/25/2018	Common Stock	23,056		23,05	56	D	
Non- Qualified Stock	\$39.055								10/24/201	13 ⁽²⁾	10/24/2019	Common	28,614		28,61	14	D	

Explanation of Responses:

(right to

- 1. Market Share Units represent a right to receive one share of Haemonetics Corporation common stock for each Market Stock Unit based on Haemonetics stock price during the 30 trading days prior to March 31, 2017. The number of Market Stock Units (and therefore the number of shares payable) will depend on the Companys stock price during such period. The Market Stock Units disclosed in column 5 represent a target amount. The number of shares ultimately issued could range from none to three times the target amount in column 5. The Market Stock Units were granted under the 2005 Haemonetics Corporation Long-Term Incentive Compensation Plan and are exempt under Rule 16b-3(d).
- 2. Grant to reporting person of right to buy shares of common stock exercisable in annual increments of 25 percent beginning on the first anniversary of the date of grant.

By: Alexander Steffan For: Warren Nighan

07/26/2013

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.